Health Condition 1: N182- Chronic kidney disease, stage 2 (mild) Health Condition 2: N183- Chronic kidney disease, stage 3 (moderate) Health Condition 3: N184- Chronic kidney disease, stage 4 (severe) Health Condition 4: N181- Chronic kidney disease, stage 1
Conditions
Interventions
Intervention1: Iohexol: a single bolus of 5 ml of iohexol (omnipaque 300) will be administered intravenously
Sponsors
Ashok Kumar Yadav
Eligibility
Inclusion criteria
Inclusion criteria: CKD subjects 1. Age more than 18 years 2. eGFR (CKD-EPI creatinine equation 2009) range less than 60 ml/min/1.73m2 to more than 15 ml/min/1.73m2 and more than 60 to less than 90 ml/min/1.73m2 with proteinuria (urine protein to creatinine ratio more than 500 mg/g or albumin to creatinine ratio more than 300 mg/g) 3. Stable clinical state for last 3 months as judged by investigator. 4. Venous sampling possible for both upper limbs 5. Able to consent Healthy subjects 1. Age: more than 18 years 2. Stable clinical state for last 3 months as judged by investigator 3. No history of any ongoing chronic illness 4. Able to consent
Exclusion criteria
Exclusion criteria: CKD subjects 1. Dialysis dependency or having received dialysis in preceding 3 months 2. Active malignancy or treatment for malignancy in last two years 3. Voiding dysfunction or problems 4. Urinary incontinence 5. Pregnancy 6. Allergy to iohexol or iodinated contrast media 7. Amputation of any limb 8. Decompensated chronic liver disease or heart failure 9. Currently receiving antibiotic therapy for systemic infection 10. Positive HIV antibody or positive Hepatitis surface antigen 11. RBC transfusion within 8 weeks before enrolment 12. Androgen therapy within 8 weeks before enrolment 13. Any chronic unstable medical condition 14. History of drug abuse 15. Sleep apnea 16. Bone and joint abnormalities that were preclude exercise testing Healthy subjects 1. History of kidney, renal stone disease or urinary tract disease 2. History of voiding difficulty or incontinence 3. History of amputation in any limb 4. History of hospitalization in last 3 months 5. Life expectancy less than 1 year as judged by investigator 6. Poor functional status as judged by investigator 7. Bed ridden subjects 8. Pregnancy or lactation in case of females 9. History of allergy to iodinated contrast media or any other known drug allergy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| â?¢The primary outcome is to develop an eGFR equation based on normalized creatinine and /or cystatin C for the Indian Population.Timepoint: Baseline, 6, 12, 18 and 24 months | — |
Secondary
| Measure | Time frame |
|---|---|
| â?¢ To establish the reference range of glomerular filtration rate in Indian Population â?¢ Reclassification of CKD into various KDIGO risk categories â?¢ Identification of factors associated with glomerular filtration rate, including but not limited to dietary protein intake, muscle mass and total fat mass. Timepoint: Baseline, 6, 12, 18 and 24 months | — |
Countries
India
Contacts
Public ContactASHOK KUMAR YADAV
PGIMER
Outcome results
None listed